3 patents currently held
31 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Apr 2032. from the record
Of the 31 now held by other companies, 9 name Ipsen Biopharm Ltd. as their current owner, and 22 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Apr 2032
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Apr 2032 · Medium confidence
Also notable
Ends Jan 2043 · High confidence
Monospecific and Bispecific ANTI-IGF-1R and ANTI-ERBB3 Antibodies
US 9,938,346
Cited by 17 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
ANTI-TNFR2 Antibodies and Uses Thereof
US 12,435,151
Granted 2025. Too new for citation comparison; protection runs to 2043.
Formerly held, still cited
Notable
Ends Aug 2028 · High confidence
The most cited patent in this portfolio, cited by 148 later US patents, top 5% of utility patents granted in 2012 in our data. Protection runs to 2028.
now held by Ipsen Biopharm Ltd.
Also notable
Ends May 2031 · Medium confidence
Cited by 57 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
now held by Silver Creek Pharmaceuticals, Inc.
Also notable
Ends Feb 2028 · High confidence
Cited by 78 later US patents, top 10% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
now held by 14NER Oncology, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Bispecific ANTI-IGF-1R and ANTI-ERBB3 Antibodies | 2 in force | to Apr 2032 |
| ANTI-TNFR2 Antibodies and Uses Thereof | 1 in force | to Jan 2043 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,476,409 | Bispecific ANTI-IGF-1R and ANTI-ERBB3 Antibodies In force · High confidence | In force | High confidence | |
| US 9,938,346 | Monospecific and Bispecific ANTI-IGF-1R and ANTI-ERBB3 Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 12,435,151 | ANTI-TNFR2 Antibodies and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 31 patents in force now held by others · 44 patents ended · 2 applications pending · 121 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
20 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed